Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase NA 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 1

Conditions

Urinary Bladder Neoplasms 3Upper Tract Urothelial Carcinomas 1Renal Pelvis and Ureter Urothelial Carcinoma 1Lung Neoplasms 1Acrocephalosyndactylia 1

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × infigratinib × Genitourinary × Clear all
NCT02657486 2026-02-09

BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Memorial Sloan Kettering Cancer Center

Phase NA Completed
4 enrolled
Genitourinary

Urinary Bladder Neoplasms

NCT04972253 2022-08-10

(BLASST)-3

Dana-Farber Cancer Institute

Phase 1 Withdrawn
Genitourinary

Acrocephalosyndactylia, Urinary Bladder Neoplasms

NCT01004224 2019-10-04

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Novartis

Phase 1 Completed
208 enrolled
GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡